MannKind Corporation (MNKD) fair value analysis
Nasdaq · Updated 2026-10-19
MNKD price how computed
Valuation status
No verdict this weekMNKD: Next year's consensus is far above both what this company earned over the last four quarters and what its most recent quarter is earning.
Our model does not publish a verdict on a forecast that far from results; it is re-evaluated weekly.
- Last price
- $3.04
- Sector
- Healthcare
- 12-month range
- $2.28–$6.21
- Market cap
- $977M
- From 52-week high
- -51.0%
- Shares outstanding
- 322M
- Rank in Healthcare by quality score
- #110 of 301
Last price is our stored weekly price from 2026-10-16, older than the 2026-10-19 run that built this page; the chart runs through 2026-10-16.
MannKind Corporation is a biopharmaceutical company that develops and commercializes therapies for patients with endocrine and genetic disorders. The company is based in the United States and operates in the healthcare sector, focusing on innovative treatment solutions for serious medical conditions.
MNKD currently ranks #110 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $977M
- P/E (trailing)
- n/m
- Revenue (TTM)
- $394M
- Net margin
- -11.1%
- EPS (TTM)
- $-0.10
- Gross margin
- 73.0%
- Debt / equity
- 0.00
- Revenue growth (3-yr avg)
- 37.8%
- Shares outstanding
- 322M
Derived indicators how computed
- Quality grade
- C
- Margin trend
- Stable
- 52-week position
- The bottom quarter of its range
Technicals how computed
- RSI (14-day)
- 37 · neutral
- 50-day average
- $3.73
- 200-day average
- $3.85
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-04
- Last 8 quarters vs consensus
- 2 beat, 6 missed
- Quarter by quarter
- 2026-06 ▼ miss (-200.0%)
2026-03 ▼ miss (-398.5%)
2025-12 ▼ miss (-400.0%)
2025-09 ▲ beat (+200.0%)
2025-06 ▼ miss (-37.5%)
2025-03 ▼ miss (-33.3%)
2024-12 ▼ miss (-25.0%)
2024-09 ▲ beat (+33.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 7 buy · 1 hold · 0 sell (8 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $7.84
- Target vs last price
- +157.9%
What our data shows for MNKD
- Our model validated 6 trailing price-to-earnings windows for MNKD, built from quarterly earnings records.
- Shares are trading in the lower third of their 12-month price range of $2.28–$6.21.
- The 14-day relative strength index sits at a neutral 37.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- MNKD's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
Recent MNKD news
TickrTrends' derived news-sentiment signal for MNKD is currently leaning positive, computed from recent coverage.
- MNKD Reiterated by Cantor Fitzgerald -- Price Target Maintained at $8.00 (gurufocus.com, 2026-10-20)
TickrTrends take: Cantor Fitzgerald's maintained price target of $8 represents analyst confidence in MNKD's current trajectory within the Healthcare sector. Given TickrTrends' concurrent undervalued assessment, the reiteration suggests the market may not yet have fully priced in the company's potential, creating a point of interest for investors focused on valuation metrics. A valuation-focused reader should monitor whether MNKD moves toward the $8 target, as this would help validate or challenge the undervalued positioning. - MannKind to Participate in the Chardan Healthcare Conference (manilatimes.net, 2026-10-14)
TickrTrends take: MannKind's participation in the Chardan Healthcare Conference provides an opportunity for the company to present its business strategy and operational updates to investors and analysts in the healthcare sector. Given TickrTrends' current undervalued assessment of MNKD, this conference appearance may serve as a platform for the company to communicate developments that could influence how the market values its assets and future prospects. Valuation-focused investors should monitor any announcements regarding pipeline progress, commercial execution, or financial guidance that emerge from the company's participation in this industry forum. - MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD) (manilatimes.net, 2026-10-10)
TickrTrends take: MannKind presented clinical data at HFSA 2026 regarding Furoscix ReadyFlow for managing edema in heart failure and chronic kidney disease patients, potentially expanding the commercial applications of its injectable furosemide platform. As a healthcare company currently valued as undervalued by TickrTrends, any expansion of Furoscix's addressable market through new clinical evidence could support stronger revenue trajectories that might justify higher valuations. Investors monitoring MNKD's valuation should track whether this data translates into regulatory approvals or payer coverage decisions that would meaningfully expand the patient population eligible for treatment.
More MNKD news
- Delaware Court Ruling Boosts MannKind (MNKD) Outlook Amid Liquidia Patent Dispute (gurufocus.com, 2026-09-30)
- MannKind (MNKD) Bets On Inhaled Weight Loss Amid Widening Losses (finance.yahoo.com, 2026-09-16)
What people are saying
Follow the MNKD conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — MNKD's sector positioning has strengthened this week, with its discount rank among Healthcare stocks improving from number 15 to number 10. This improvement indicates the company is trading at a more favorable valuation relative to other Healthcare sector peers. The current valuation verdict remains Undervalued.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — MNKD's technical positioning improved this week as its Relative Strength Index moved out of oversold territory into neutral range. The company's valuation ranking within the Healthcare sector also strengthened, rising to number 14 in sector discount ranking from number 22, indicating the stock is trading at a more attractive relative valuation compared to its healthcare peers. The current valuation verdict remains Undervalued.
- 2026-10-05 — MNKD's position within the Healthcare sector has shifted this week, with its sector discount rank declining from number 15 to number 22. The company maintains an undervalued valuation verdict according to TickrTrends' derived indicators. This change reflects a movement toward less favorable valuation positioning relative to other Healthcare sector companies.
- 2026-09-28 — MNKD's relative valuation position improved this week as its sector discount rank moved from number 24 to number 15, indicating it has become more attractively valued compared to other healthcare companies. The stock maintains an undervalued verdict according to TickrTrends' derived indicators. This strengthening in the discount ranking suggests the company's valuation metrics have become more favorable within the healthcare sector.
- 2026-09-21 — MNKD's technical positioning shifted this week as its Relative Strength Index moved from the neutral zone into oversold territory, suggesting the stock may have experienced selling pressure. The company remains in the Healthcare sector and maintains an undervalued classification according to current valuation metrics.
- 2026-09-17 — No material change this week: the verdict, bands and grades all held steady.
Frequently asked questions
Is MNKD stock undervalued?
MNKD does not yet have sufficient validated earnings history for a full Forward Fair Value verdict under TickrTrends' standards; it is re-evaluated every week.
What is MNKD's TickrTrends verdict?
MNKD is currently marked 'Awaiting full valuation' - a verdict publishes automatically once at least six validated trailing P/E windows accumulate.
How does MNKD compare to other Healthcare stocks?
MNKD ranks #110 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is MNKD overbought or oversold?
MNKD's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does MNKD report earnings next?
MNKD's next earnings report is scheduled for 2026-11-04, per the published earnings calendar.
Does MNKD usually beat earnings estimates?
Over its last 8 reported quarters MNKD beat the consensus estimate 2 times and missed 6 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about MNKD?
Of 8 analysts covering MNKD, 7 rate it a buy, 1 a hold and 0 a sell - buy-leaning, with a consensus price target of $7.84 (+157.9% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.